Evidence map›Paper›PMID 29732570›Full record

ArticleThe Journal of pathology2018

CD206-positive myeloid cells bind galectin-9 and promote a tumor-supportive microenvironment.

Elizabeth Ann L Enninga, Kyriakos Chatzopoulos, John T Butterfield, Shari L Sutor, Alexey A Leontovich, Wendy K Nevala, Thomas J Flotte, Svetomir N Markovic

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 57 citations in OpenAlex.

  1. Review
  2. Galectin-9-An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy.International journal of molecular sciences · 2025
    Review
  3. Article
  4. Review
  5. Review
  6. Galectin-9: diverse roles in skin disease.Frontiers in allergy · 2025
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Elizabeth Ann L EnningaDepartment of Oncology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0003-3621-7335
Kyriakos ChatzopoulosDepartment of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota, USA.
John T ButterfieldDepartment of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Shari L SutorDepartment of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Alexey A LeontovichDepartment of Bioinformatics and Statistics, Mayo Clinic, Rochester, Minnesota, USA.
Wendy K NevalaDepartment of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Thomas J FlotteDepartment of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Svetomir N MarkovicDepartment of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Mayo Clinic · US

Funding

Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic SiteU10CA180790 · NCI · MAYO CLINIC ROCHESTER · PI ALBERTS, STEVEN R, BOUGHEY, JUDY CAROLINE · 2014 to 2018
$6.6M
NCATS NIH HHS UL1 TR000135NCI NIH HHS U10 CA180790
6 · The paper itself

Abstract

In patients with metastatic melanoma, high blood levels of galectin-9 are correlated with worse overall survival and a bias towards a Th2 inflammatory state supportive of tumor growth. Although galectin-9 signaling through TIM3 on T cells has been described, less is known about the interaction of galectin-9 with macrophages. We aimed to determine whether galectin-9 is a binding partner of CD206 on macrophages and whether the result of this interaction is tumor-supportive. It was determined that incubation of CD68

Indexed as

Tumor MicroenvironmentAdultAgedAged, 80 and overCell ProliferationChemokine CCL2Chemokine CCL22FemaleFibroblast Growth Factor 2GalectinsHumansLectins, C-TypeMacrophagesMaleMannose-Binding LectinsMannose ReceptorCCL22 protein, humanCCL2 protein, humanChemokine CCL2Chemokine CCL22Fibroblast Growth Factor 2GalectinsLectins, C-TypeLGALS9 protein, humanMannose-Binding LectinsMannose ReceptorReceptors, Cell SurfaceangiogenesisCD206galectin-9macrophagesmetastatic melanomamonocytestumor microarray

Identifiers

PMID29732570
PMCPMC6935353
OpenAlexW2801533129

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.